דוננמב (Hebrew Wikipedia)

Analysis of information sources in references of the Wikipedia article "דוננמב" in Hebrew language version.

refsWebsite

Global rank Hebrew rank

7doi.org

2^nd place

10^th place

6nih.gov

4^th place

18^th place

2web.archive.org

1^st place

6^th place

2fda.gov

447^th place

285^th place

1alzforum.org

low place

1nytimes.com

7^th place

32^nd place

alzforum.org

Mark Mintun of Eli Lilly & Company, Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit, alzforum, ‏19/03/2021 (באנגלית)

doi.org

dx.doi.org

Mark A. Mintun, Albert C. Lo, Cynthia Duggan Evans, Alette M. Wessels, Paul A. Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks, John R. Sims, Miroslaw Brys, Liana G. Apostolova, Stephen P. Salloway, Daniel M. Skovronsky, Donanemab in Early Alzheimer's Disease, The New England Journal of Medicine 384, 2021-05-06, עמ' 1691–1704 doi: 10.1056/NEJMoa2100708 (באנגלית)
Justin M. Long, David M. Holtzman, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies, Cell 179, 2019-10-03, עמ' 312–339 doi: 10.1016/j.cell.2019.09.001 (באנגלית)
Ronald B. Demattos, Jirong Lu, Ying Tang, Margaret M. Racke, Cindy A. Delong, John A. Tzaferis, Justin T. Hole, Beth M. Forster, Peter C. McDonnell, Feng Liu, Robert D. Kinley, William H. Jordan, Michael L. Hutton, A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice, Neuron 76, 2012-12-06, עמ' 908–920 doi: 10.1016/j.neuron.2012.10.029 (באנגלית)
Gilbert Gallardo, David M. Holtzman, Amyloid-β and Tau at the Crossroads of Alzheimer's Disease, Advances in Experimental Medicine and Biology 1184, 2019, עמ' 187–203 doi: 10.1007/978-981-32-9358-8_16 (באנגלית)
Stephen Loucian Lowe, Brian A. Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R. Sims, Donanemab (LY3002813) dose-escalation study in Alzheimer's disease, Alzheimer's & Dementia (New York, N. Y.) 7, 2021, עמ' e12112 doi: 10.1002/trc2.12112 (באנגלית)
John R. Sims, Jennifer A. Zimmer, Cynthia D. Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Paul Solomon, Stephen Salloway, Liana G. Apostolova, Oskar Hansson, Craig Ritchie, Dawn A. Brooks, Mark Mintun, Daniel M. Skovronsky, TRAILBLAZER-ALZ 2 Investigators, Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, JAMA 330, 2023-08-08, עמ' 512–527 doi: 10.1001/jama.2023.13239 (באנגלית)
Emily Harris, FDA Greenlights Second Alzheimer Drug, Donanemab, JAMA, 2024-07-26 doi: 10.1001/jama.2024.13386 (באנגלית)

fda.gov

accessdata.fda.gov

"Kisunla (donanemab-azbt) injection, for intravenous use" (PDF). ארכיון (PDF) מ-2 ביולי 2024. נבדק ב-2 ביולי 2024. {{cite web}}: (עזרה)

fda.gov

Center for Drug Evaluation and Research, FDA approves treatment for adults with Alzheimer’s disease, FDA, 2024-07-02 (באנגלית)

nih.gov

pubmed.ncbi.nlm.nih.gov

Mark A. Mintun, Albert C. Lo, Cynthia Duggan Evans, Alette M. Wessels, Paul A. Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks, John R. Sims, Miroslaw Brys, Liana G. Apostolova, Stephen P. Salloway, Daniel M. Skovronsky, Donanemab in Early Alzheimer's Disease, The New England Journal of Medicine 384, 2021-05-06, עמ' 1691–1704 doi: 10.1056/NEJMoa2100708 (באנגלית)
Justin M. Long, David M. Holtzman, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies, Cell 179, 2019-10-03, עמ' 312–339 doi: 10.1016/j.cell.2019.09.001 (באנגלית)
Ronald B. Demattos, Jirong Lu, Ying Tang, Margaret M. Racke, Cindy A. Delong, John A. Tzaferis, Justin T. Hole, Beth M. Forster, Peter C. McDonnell, Feng Liu, Robert D. Kinley, William H. Jordan, Michael L. Hutton, A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice, Neuron 76, 2012-12-06, עמ' 908–920 doi: 10.1016/j.neuron.2012.10.029 (באנגלית)
Gilbert Gallardo, David M. Holtzman, Amyloid-β and Tau at the Crossroads of Alzheimer's Disease, Advances in Experimental Medicine and Biology 1184, 2019, עמ' 187–203 doi: 10.1007/978-981-32-9358-8_16 (באנגלית)
Stephen Loucian Lowe, Brian A. Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R. Sims, Donanemab (LY3002813) dose-escalation study in Alzheimer's disease, Alzheimer's & Dementia (New York, N. Y.) 7, 2021, עמ' e12112 doi: 10.1002/trc2.12112 (באנגלית)
John R. Sims, Jennifer A. Zimmer, Cynthia D. Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Paul Solomon, Stephen Salloway, Liana G. Apostolova, Oskar Hansson, Craig Ritchie, Dawn A. Brooks, Mark Mintun, Daniel M. Skovronsky, TRAILBLAZER-ALZ 2 Investigators, Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, JAMA 330, 2023-08-08, עמ' 512–527 doi: 10.1001/jama.2023.13239 (באנגלית)

nytimes.com

Belluck, Pam (2 ביולי 2024). "New Drug Approved for Early Alzheimer's". The New York Times. ארכיון מ-2 ביולי 2024. נבדק ב-3 ביולי 2024. {{cite news}}: (עזרה)

web.archive.org

"Kisunla (donanemab-azbt) injection, for intravenous use" (PDF). ארכיון (PDF) מ-2 ביולי 2024. נבדק ב-2 ביולי 2024. {{cite web}}: (עזרה)
Belluck, Pam (2 ביולי 2024). "New Drug Approved for Early Alzheimer's". The New York Times. ארכיון מ-2 ביולי 2024. נבדק ב-3 ביולי 2024. {{cite news}}: (עזרה)